IO Biotech, Inc. (IOBT)

1.3100 +0.0300 (+2.34%) 收市：04:00PM EDT

IO Biotech, Inc.

Ole Maaløes Vej 3
Copenhagen N
Copenhagen 2200
Denmark
45 70 70 29 80
https://www.iobiotech.com

版塊: Healthcare
行業: Biotechnology
全職員工: 70

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Mai-Britt Zocca Ph.D.	Founder, President, CEO, Principal Financial Officer & Director	892.24k	無	1968
Mr. Devin Whittemore Smith	Secretary, General Counsel & Chief Compliance Officer	621.8k	無	1968
Dr. Qasim Iftikhar Ahmad M.D.	Chief Medical Officer	503.28k	無	1971
Prof. Inge Marie Svane M.D., Ph.D.	Founder & Clinical Advisor	無	無	無
Prof. Mads Hald Andersen M.D., Ph.D.	Founder & Scientific Advisor	無	無	無
Anders Ljungqvist	Founder	無	無	無
Prof. Per Thor Straten	Founder	無	無	無
Ms. Amy B. Sullivan M.B.A.	Chief Financial Officer	391.24k	無	1971
Mr. Eric Faulkner M.B.A.	Chief Technical Officer	無	無	無
Mr. Daniel G. Mannix Ph.D.	Senior Vice President of Regulatory Affairs	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

公司管治

截至 無 止，IO Biotech, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。